Avita Medical (NASDAQ:RCEL – Get Free Report) and Nanovibronix (NASDAQ:FEED – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.
Institutional and Insider Ownership
27.7% of Avita Medical shares are owned by institutional investors. Comparatively, 16.4% of Nanovibronix shares are owned by institutional investors. 2.2% of Avita Medical shares are owned by insiders. Comparatively, 12.2% of Nanovibronix shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Analyst Ratings
This is a summary of recent recommendations for Avita Medical and Nanovibronix, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Avita Medical | 1 | 1 | 5 | 0 | 2.57 |
| Nanovibronix | 1 | 0 | 0 | 0 | 1.00 |
Earnings and Valuation
This table compares Avita Medical and Nanovibronix”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Avita Medical | $71.61 million | 4.37 | -$48.59 million | ($1.44) | -7.06 |
| Nanovibronix | $1.93 million | 1.74 | -$18.18 million | ($9.77) | -0.37 |
Nanovibronix has lower revenue, but higher earnings than Avita Medical. Avita Medical is trading at a lower price-to-earnings ratio than Nanovibronix, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
Avita Medical has a beta of 2.02, suggesting that its share price is 102% more volatile than the S&P 500. Comparatively, Nanovibronix has a beta of 1.38, suggesting that its share price is 38% more volatile than the S&P 500.
Profitability
This table compares Avita Medical and Nanovibronix’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Avita Medical | -56.96% | N/A | -78.53% |
| Nanovibronix | -1,093.61% | -60.73% | -48.48% |
Summary
Avita Medical beats Nanovibronix on 10 of the 14 factors compared between the two stocks.
About Avita Medical
AVITA Medical, Inc., together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions. It develops RECELL GO to control the manual process of disaggregation, filtration, and soak time. The company was formerly known as AVITA Therapeutics, Inc. AVITA Medical, Inc. was incorporated in 2020 and is headquartered in Valencia, California.
About Nanovibronix
NanoVibronix Inc. is a medical device company that is focused on creating medical products utilizing its proprietary low-intensity, surface acoustic wave technology. … NanoVibronix’ catheter-based products include the UroShield™ and NG-Shield™ devices that are both CE mark certified.
Receive News & Ratings for Avita Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avita Medical and related companies with MarketBeat.com's FREE daily email newsletter.
